5-Amino-1MQ

5-Amino-1MQ, chemically 5-amino-1-methylquinolinium, is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It belongs to a series of methylquinolinium compounds carrying a primary amine substituent, a design chosen because it combines high selectivity for NNMT with strong membrane permeability, allowing the molecule to cross cell membranes and reach its intracellular target ^[1]. NNMT itself is a cytosolic metabolic enzyme that sits at the intersection of energy metabolism and epigenetic regulation, using the universal methyl donor S-adenosyl methionine (SAM) to methylate nicotinamide, a precursor of nicotinamide adenine dinucleotide (NAD) ^[2].

Interest in NNMT as a drug target grew from the observation that the enzyme is over-expressed in the white adipose tissue and liver of obese and insulin-resistant animals and humans, where its activity depletes NAD and consumes methyl groups, promoting fat storage and metabolic dysfunction ^[2][3]. Inhibiting NNMT is therefore expected to restore NAD levels, preserve cellular methylation capacity, and favor energy expenditure over lipid storage. 5-Amino-1MQ emerged from medicinal-chemistry efforts to produce exactly such an inhibitor, and it became a prototype cell-permeable NNMT inhibitor used to validate the target in living animals ^[1].

Research applications center on obesity, type 2 diabetes, metabolic syndrome, and, more recently, cardiometabolic and age-related conditions; NNMT inhibition has been explored in models ranging from diet-induced obesity to heart failure with preserved ejection fraction ^[1][3][4]. Its regulatory status is that of an investigational research chemical; 5-Amino-1MQ is not an approved drug or dietary supplement, and no human clinical trials of NNMT inhibitors had been documented in the reviewed literature, so it circulates chiefly as a research-grade compound, typically supplied as an oral capsule or powder ^[3]. Its rising popularity reflects the broader enthusiasm for NAD-centered approaches to weight management and longevity.

Human safety data is essentially absent: 5-Amino-1MQ is a preclinical research compound with no completed human trials, so its profile in people is uncharacterized. Animal studies to date have not flagged major toxicity, but appropriate dosing, long-term effects, and drug interactions remain unknown. Handle as an experimental, research-only material.

5-Amino-1MQ (5-amino-1-methylquinolinium) emerged from a wave of research that identified nicotinamide N-methyltransferase (NNMT) as a metabolic target in obesity and type 2 diabetes, a line of work that gained momentum in the mid-2010s after antisense knockdown of the enzyme was shown to protect mice from diet-induced obesity. As interest turned toward drug-like inhibitors, small-molecule methylquinolinium compounds including 5-Amino-1MQ were reported around 2017 and 2018 as selective, membrane-permeable NNMT inhibitors that reduced body weight and adiposity in obese mice.

Because it is a relatively recent research chemical rather than an approved medicine, its detailed discovery record is thinner than that of older peptides, and much of the published characterization concerns its enzyme target and preclinical metabolic effects. It remains an investigational compound used in research rather than a clinically approved therapy.

5-Amino-1MQ has become one of the most talked-about compounds in the metabolic and longevity communities, prized for a mechanism that feels genuinely novel: instead of stimulating the nervous system or blunting appetite, it reprograms fat cells by restoring NAD and methyl-group balance. Enthusiasts point to preclinical results in which related inhibitors reduced body weight, shrank fat cells, and lowered cholesterol without cutting food intake, an appealing profile compared with conventional stimulant-based fat loss.

Its oral activity and its link to the fashionable NAD and sirtuin biology add to the buzz. Candor is warranted, however, because the supporting evidence is almost entirely from cell and animal studies, human clinical trials are lacking, and long-term safety in people is not established. For now it is best understood as a promising research molecule rather than a proven intervention.